Cerit Ethem Turgay, Ağbaht Kemal, Demir Özgür, Şahin Mustafa, Gedik Vedia Tonyukuk, Özcan Cem, Çorapçıoğlu Demet
Endocr Pract. 2016 Dec;22(12):1422-1428. doi: 10.4158/EP161295.OR. Epub 2016 Sep 15.
Discordance between insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels is an important problem in the follow-up of patients diagnosed with acromegaly. Our aims were to evaluate the discordance between IGF-1 and GH levels and compare the performance of different cut-off levels for the nadir in GH (GHn) in acromegalic patients.
The study included 63 acromegalic patients in a follow-up at a tertiary care university hospital facility. Levels of IGF-1, IGF binding protein-3 (IGFBP-3), and GH were investigated. The baseline GH and GHn levels were evaluated after an oral glucose tolerance test (cut-offs of 0.4 and 1 ng/mL, respectively). The discordance rates between GHn and IGF-1 levels, and IGF-1/IGFBP-3 ratios were determined.
We first adopted a GHn cut-off value of 1 ng/mL and found that 27 patients (42.9%) exhibited biochemical remission (BR) (IGF-1 <95 percentile, GH <1), and 25 patients (39.7%) had no BR (NBR) (IGF-1 ≥95 percentile, GH >1). Discordance in the presence of normal IGF-1 and nonsuppressed GH (DC1) occurred in 2 of 63 (3.2%) patients; discordance in the presence of high IGF-1 and suppressed GH (DC2) occurred in 9 of 63 (14.3%) patients. If the GHn cut-off value adopted was 0.4 ng/mL, the distributions were 17 of 63 (27.0%) patients in BR, 29 of 63 (46.0%) patients in NBR, 12 of 63 (19.0%) in DC1, and 5 of 63 (7.9%) patients in DC2. If only the baseline GH values were considered, the distributions were very similar to those with a GHn cut-off value of 0.4 ng/mL. The IGF-1/IGFBP-3 ratio was lowest in the BR group.
Adopting a GHn cut-off value of 0.4 ng/mL did not increase the test performance compared with baseline GH only. In contrast, in the follow-up of acromegalic patients, the IGF-1/IGFBP-3 ratio might be a useful measurement when discordance between IGF-1 and GH levels occurs. We propose that these values be considered in clinical practice.
BR = biochemical remission DC1 = discordance group 1 DC2 = discordance group 2 DM = diabetes mellitus GH = growth hormone GHn = nadir in GH IGF-1 = insulin-like growth factor-1 IGFBP-3 = IGF binding protein-3 LAR = long-acting release NBR = not in biochemical remission OGTT = oral glucose tolerance test.
胰岛素样生长因子-1(IGF-1)与生长激素(GH)水平不一致是肢端肥大症患者随访中的一个重要问题。我们的目的是评估IGF-1与GH水平之间的不一致性,并比较肢端肥大症患者中GH最低点(GHn)不同截断值的性能。
该研究纳入了一家三级医疗大学医院设施中63例接受随访的肢端肥大症患者。对IGF-1、IGF结合蛋白-3(IGFBP-3)和GH水平进行了研究。口服葡萄糖耐量试验后评估基线GH和GHn水平(截断值分别为0.4和1 ng/mL)。确定了GHn与IGF-1水平之间以及IGF-1/IGFBP-3比值的不一致率。
我们首先采用1 ng/mL的GHn截断值,发现27例患者(42.9%)表现出生化缓解(BR)(IGF-1<第95百分位数,GH<1),25例患者(39.7%)未达到生化缓解(NBR)(IGF-1≥第95百分位数,GH>1)。63例患者中有2例(3.2%)出现IGF-1正常且GH未被抑制的不一致情况(DC1);63例患者中有9例(14.3%)出现IGF-1升高且GH被抑制的不一致情况(DC2)。如果采用的GHn截断值为0.4 ng/mL,分布情况为63例患者中有17例(27.0%)处于BR,63例患者中有29例(46.0%)处于NBR,63例患者中有12例(19.0%)处于DC1,63例患者中有5例(7.9%)处于DC2。如果仅考虑基线GH值,分布情况与GHn截断值为0.4 ng/mL时非常相似。BR组的IGF-1/IGFBP-3比值最低。
与仅使用基线GH相比,采用0.4 ng/mL的GHn截断值并未提高检测性能。相反,在肢端肥大症患者的随访中,当IGF-1与GH水平出现不一致时,IGF-1/IGFBP-3比值可能是一个有用的测量指标。我们建议在临床实践中考虑这些值。
BR = 生化缓解;DC1 = 不一致组1;DC2 = 不一致组2;DM = 糖尿病;GH = 生长激素;GHn = GH最低点;IGF-1 = 胰岛素样生长因子-1;IGFBP-3 = IGF结合蛋白-3;LAR = 长效释放;NBR = 未达到生化缓解;OGTT = 口服葡萄糖耐量试验